Apple shares plummet after analyst downgrade - Eli Lilly hits new all-time high

Apple shares plummet after analyst downgrade - Eli Lilly hits new all-time high

According to a report by www.finanzen.net, Apple shares fell 3.58 percent to $185.64 in NASDAQ trading after Barclays analysts downgraded the shares from “Equal Weight” to “Underweight” and slightly lowered the price target due to expected weak demand for the latest iPhone.

This downgrade of Apple shares by Barclays has a significant impact on the technology market, particularly demand for Apple products. Barclays' assessment could cause investors and consumers to lose confidence in the company and its products, which could lead to a decline in sales and ultimately a decline in revenue. Additionally, this could also impact other technology companies that are heavily dependent on Apple, as the company's sales figures have an impact on the entire industry.

The downgrade of the shares could also affect investor confidence in the company and lead to a decline in the share price. This could lead to further losses for investors and also weaken overall confidence in the stock market.

It is important to note that analysts' forecasts and assessments can have a significant impact on the market as they influence the behavior of investors and consumers. Therefore, investors and consumers should monitor developments closely and make informed decisions based on well-founded information.

This downgrade and expected weak demand for Apple's latest iPhone could worsen market conditions for the company and the technology industry as a whole. It remains to be seen how these developments will play out in the coming weeks and months.